|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 慢性病毒性肝炎发病机制的分子生物学研究显示文摘由乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)的感染引起的急性和慢性肝病目前还没有满意的治疗方法.新型治疗方法和治疗药物的研究开发,依赖于肝炎病毒致病的分子生物学机制的研究进展.关于HBV感染个体准种概念的引入,使我们对于HBV基因变异的研究,从单一病毒的基因变异上升到群体病毒的基因变异?从静态的基因突变上升到动态的基因变异,从而对HBV存在状态的看法发生了根本的改变.HBV感染肝细胞的相关受体蛋白虽然进行了多年的研究,但还没有最终确定.利用新型技术对于HBV表面抗原蛋白的结合蛋白进行筛选是一个重要的方向.HBV和HCV感染与肝细胞癌之间的关系已经得到确定,但是具体的分子生物学机制还有许多工作要做.研究这2种肝炎病毒反式激活作用的把基因是阐明其引起肝细胞癌分子生物学机制的重要途径.在肝细胞中表达的肝炎病毒蛋白不是孤立存在的,或者与其自身结合形成同二聚体,或者与病毒的其他蛋白?肝细胞蛋白结合形成异二聚体,从而对于肝细胞的生长?代谢?甚至是恶性转化产生重要影响. | 成军 | 2002 | 世界华人消化杂志2002，10，2： | 141 |
| 2 | A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus显示文摘AIM:To determine the therapeutic effect of lamivudine in late pregnancy for the interruption of motherto-child transmission(MTCT) of hepatitis B virus(HBV).METHODS:Studies were identified by searching available databases up to January 2011.Inclusive criteria were HBV-carrier mothers who had been involved in randomized controlled clinical trials(RCTs) with lamivudine treatment in late pregnancy,and newborns or infants whose serum hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg) or HBV DNA had been documented.The relative risks(RRs) for interruption of MTCT as indicated by HBsAg,HBV DNA or HBeAg of newborns or infants were calculated with 95% confidence interval(CI) to estimate the efficacy of lamivudine treatment.RESULTS:Fifteen RCTs including 1693 HBV-carrier mothers were included in this meta-analysis.The overall RR was 0.43(95% CI,0.25-0.76;8 RCTs;Pheterogeneity = 0.04) and 0.33(95% CI,0.23-0.47;6 RCTs;Pheterogeneity = 0.93) indicated by newborn HBsAg or HBV DNA.The RR was 0.33(95% CI,0.21-0.50;6 RCTs;Pheterogeneity = 0.46) and 0.32(95% CI,0.20-0.50;4 RCTs;Pheterogeneity = 0.33) indicated by serum HBsAg or HBV DNA of infants 6-12 mo after birth.The RR(lamivudine vs hepatitis B immunoglobulin) was 0.27(95% CI,0.16-0.46;5 RCTs;Pheterogeneity = 0.94) and 0.24(95% CI,0.07-0.79;3 RCTs;P heterogeneity = 0.60) indicated by newborn HBsAg or HBV DNA,respectively.In the mothers with viral load < 106 copies/mL after lamivudine treatment,the efficacy(RR,95% CI) was 0.33,0.21-0.53(5 RCTs;Pheterogeneity = 0.82) for the interruption of MTCT,however,this value was not significant if maternal viral load was > 106 copies/mL after lamivudine treatment(P = 0.45,2 RCTs),as indicated by newborn serum HBsAg.The RR(lamivudine initiated from 28 wk of gestation vs control) was 0.34(95% CI,0.22-0.52;7 RCTs;Pheterogeneity = 0.92) and 0.33(95% CI,0.22-0.50;5 RCTs;Pheterogeneity = 0.86) indicated by newborn HBsAg or HBV DNA.The incidence of adverse effects of lamivudine was not higher in the mothers than in controls(P = 0.97).Only one study reported side effects of lamivudine in newborns.CONCLUSION:Lamivudine treatment in HBV carriermothers from 28 wk of gestation may interrupt MTCT of HBV efficiently.Lamivudine is safe and more efficient than hepatitis B immunoglobulin in interrupting MTCT.HBV MTCT might be interrupted efficiently if maternal viral load is reduced to < 106 copies/mL by lamivudine treatment. | Lei Han Hong-Wei Zhang Jia-Xin Xie Qi Zhang Hong-Yang Wang Guang- Wen Cao | 2011 | World Journal of Gastroenterology2011，17，38： | 61 |
| 3 | Methodologic research on TIMP-1,TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance显示文摘AIM: To set up a new method to detect tissue inhibitors ofmetalloproteinase1 and -2(TIMP-1 and TIMP-2) in sero ofpatients with hepatic cirrhosis, and to investigate theexpression and location of TIMP-1 and TIMP-2 in liver tissueof patients with hepatic cirrhosis, and the correlationbetween TIMPs in liver and those in sera so as to discusswhether TIMPs can be used ss a diagnosis index of hepaticfibrosisMETHODS: The monoclonal antibodies (McAbs) of TIMP-1and TIMP-2 were used to sensitize erythrocytes, and solid-phase absorption to sensitized erythrocytes (SPASE) wasused to detect TIMP-1 and TIMP-2 in the sera of patients withhepatic cirrhosis. Meanwhile, with the method of in situhybridization and immunohistochemistry, we studied themRNA expression and antigen location of TIMP-1 and TIMP-2in the livers of 40 hepatic cirrhosis patients with pathologicdiagnosis.RESULTS: With SPASE, they were 16.4 % higher in theacute hepatitis group, 33.3 % higher in the chronic hepatitisgroup, and the positive rates were 73.6 % and 61. 2 %respectively in sero of hepatic cirrhosis patients, which wereremarkably higher than those in chronic hepatitis and acutehepatitis group ( P < 0. 001 ). In 40 samples of hepaticcirrhosis tissues, all of them showed positive expression ofTIMP-1 and TIMP-2 mRNA detected withimmunohistochemistry or in situ hybridization (positive ratewas 100 % ). Expression of TIMPs in different degrees couldbe found in liver tissue with cirrhosis. TIMPs were located incytoplasm of liver cells of patients with hepatic cirrhosis.There was a significant correlation between serum TIMPslevel and liver TIMPs level.CONCLUSION: SPASE is a useful method to detect the TIMP-1 and TIMP-2 in sera of patients with hepatic cirrhosis, andTIMP-1 and TIMP-2 can be considered as a useful diagnosticindex of hepatic fibrosis, especially TIMP-1. | Oing-He Nie Yong-Oian Cheng Yu-Mei Xie Yong-Xing Zhou Bai-Xian Guang Yi-Zhan Cao,The Centre of Diagnosis and Treatment for Infectious Disease of Chinese PLA,Tangdu Hospital,Fourth Military Medical University,Xi’an 710038,Shanxi Province,China | 2002 | World Journal of Gastroenterology2002，8，2： | 51 |
| 4 | Interruption of HBV intrauterine transmission:A clinical study显示文摘AIM: To investigate the effect of hepatitis B virus (HBV)specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.METHODS: Each subject in the HBIG group (56 cases)was given 200 IU HBIG intramuscularly (im.) every 4weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) every day from 28-wk of gestation until the 30th day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.RESULTS: Reductions of HBV DNA in both treatments were significant (P<0.05). The rate of neonatal intrauterine HBV infection was significantly lower in HBIG group (16.1%)and lamivudine group (16.3 %) compared with control group (32.7 %) (P<0.05), but there was no significant difference between HBIG group and lamivudine group (P>0.05). No side effects were found in all the pregnant women or their newborns.CONCLUSION: The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3rd trimester of HBsAg positive pregnant women. | Xiao-MaoLi Yue-Boyang Hong-YingHou Zhong-JieShi Hui-MinSHen Ben-QiTeng Ai-MinLi Min-FengShi LingZou | 2003 | World Journal of Gastroenterology2003，9，7： | 53 |
| 5 | 应用噬菌体表面展示技术筛选丙型肝炎病毒NS5A抗原模拟表位显示文摘目的:筛选丙型肝炎病毒(HCV)非结构蛋白NS5A(HCVNS5A)特异性噬菌体模拟表位,为抗HCV的疫苗研究探索新途径.方法:应用噬菌体表面展示技术,以抗-HCVNS5A的单克隆抗体作为固相筛选分子,对人工合成的噬菌体随机12肽库进行5轮“吸附-洗脱-扩增”的筛选过程,随机挑取30个克隆,经噬菌体酶联免疫吸附法(ELISA)鉴定并进行交叉反应实验以及竞争抑制性结合实验,最后对所选克隆进行DNA序列分析,以确定HCVNS5A抗原的模拟表位.结果:经噬菌体富集后,从随机筛选的30个克隆中得到12个阳性克隆,确定氨基酸序列XXXPXXXLLRXX为HCVNS5A的模拟表位.结论:用噬菌体12肽库成功筛选得到HCVNS5A的模拟表位,为开展用HCV模拟表位探索HCV的防治研究创造了条件. | 钟彦伟 成军 陈新华 王刚 洪源 王琳 李莉 张玲霞 陈菊梅 | 2002 | 世界华人消化杂志2002，10，2： | 50 |
| 6 | 清除乙型肝炎病毒的非细胞裂解机制显示文摘乙型肝炎病毒(HBV)的感染过程,也是机体清除HBV的过程,两者密不可分。近年来的研究表明,除了细胞裂解并清除HBV感染的机制以外,还存在清除HBV的非细胞裂解机制,而后者更具有实际应用价值,因为在达到清除HBV的目的同时,还能不损伤HBV感染的肝细胞,或者只有很轻程度的肝细胞损害。研究中发现干扰素、白介素、肿瘤坏死因子、一氧化氮以及一些未知蛋白质因子的参与,是清除HBV的非细胞裂解机制的重要因素。研究清除HBV的非细胞裂解机制,具有十分重要的实际应用前景。 | 成军 李莉 | 2002 | 世界华人消化杂志2002，10，1： | 49 |
| 7 | Mechanism of intrauterine infection of hepatitis B virus显示文摘AIM:To explore the possible mechanism of intrauterine infection of hepatitis B virus (HBV).METHODS: HBV DNA was detected in vaginal secretion and amniotic fluid from 59 HBsAg-positive mothers and in venous blood of their newborns by PCR. HBsAg and HBcAg in placenta were determined by ABC immunohistochemistry.RESULTS:The rate of HBV intrauterine infection was 40.1% (24/59). HBV DNA was detected in 47.5% of amniotic fluid samples and 52.5% of vaginal secretion samples respectively.HBsAg and HBcAg were detected in placentas from HBsAg-positive mothers. The concentration of the two antigens decreased from the mother's side to the fetus's side, in the following order:maternal decidual cells>trophoblastic cells> villous mesenchymal cells>villous capillary endothelial cells. However, in 4 placentas the distribution was in the reverse order. HBsAg and HBcAg were detected in amniotic epithelial cells from 32 mothers.CONCLUSION:The main route of HBV transmission from mother to fetus is transplacental, from the mother side of placenta to the fetus side. However, HBV intrauterine infection may take place through other routes. | Shu-LinZhang Ya-FeiYue Gui-QinBai LeiShi HuiJiang | 2004 | World Journal of Gastroenterology2004，10，3： | 48 |
| 8 | 乙肝免疫球蛋白阻断乙肝病毒母婴垂直传播的研究显示文摘目的探讨乙型肝炎表面抗原(HBsAg)携带者孕妇及其新生儿应用乙肝免疫球蛋白(HBIG)对阻断乙肝母婴传播的效果。方法HBIG组(A组)66例,于孕28、32、36w分别注射HBIG 200IU,非HBIG组(B组)68例仅常规产前检查及监护。新生儿分为Ⅰ、Ⅱ、Ⅲ组,Ⅰ、Ⅱ组新生儿注射HBVac 10μg和HBIG 100 IU,Ⅲ组新生儿只注射HBVac 10μg。结果HBIG组较非HBIG组新生儿出生时外周血HBsAg阳性率显著降低,P<0.05。Ⅰ、Ⅱ、Ⅲ组婴儿6月龄HBsAb阳转率Ⅰ>Ⅱ>Ⅲ。结论对乙肝病毒携带孕妇孕晚期应用HBIG可以显著降低新生儿外周血HBsAg阳性率;HBsAg携带孕妇孕晚期应用HBIG,新生儿出生时应用HBIG和HBVac联合免疫,可以显著提高婴儿6月龄HBsAb。 | 孟钊 肖小敏 何明娇 徐玉苑 李耘 | 2005 | 中国优生与遗传杂志2005，13，9： | 18 |
| 9 | 病毒性肝炎肝硬变危险因素的5年追踪调查显示文摘目的探讨肝炎后肝硬变形成的危险因素.方法建立一人一卡,每年随访和门诊检查一次,对贵州省5家医院2250例乙肝患者进行5a 追踪调查及干预对照试验,5a后追踪率达90.28%.调查内容包括性别、年龄、吸烟史、饮酒史、蛋白摄入水平、乙肝家族史、负性因素(即心理因素,如:亲人死亡、意外打击、家庭不和、工作不顺、对疾病的恐惧、焦虑等)及治疗史,采用 X^2检验各种单因素,有显著意义者再分别计算其相对危险度(RR)值及其可信区间(95%CI),观察与肝炎后肝硬变形成相关的危险因素.干预组定期给予预防肝硬变的卫生健康知识强化宣传,提出合理饮食、戒酒及心理咨询、定期服用保肝药等.结果 HBeAg、抗-HBe、HBVDNA(RR 值1.21~9.82)、抗-HCV(RR 值5.50)持续阳性、乙肝家族史(RR 值14.71)、饮酒(RR 值9.82)、低蛋白饮食(RR 值6.64),心理因素(RR 值8.92)与肝硬变形成相关.干预对照试验表明,5a 后干预组肝硬变的发生率10.58%,对照组为22.91%(P<0.05).结论乙肝病毒(HBV)持续复制、合并丙肝病毒(HCV)感染、乙肝家族史、饮酒、低蛋白饮食及心理因素是肝炎后肝硬变形成的危险因素. | 吴君 程明亮 丁一生 刘仁才 李佳 王万灵 胡莲 | 2000 | 世界华人消化杂志2000，8，12： | 18 |
| 10 | 子宫内乙型肝炎病毒感染对新生儿免疫接种的影响显示文摘目的 探讨乙型肝炎病毒 (HBV)侵犯新生儿外周血单个核细胞 (PBMC) ,对新生儿免疫接种的影响 ,并从白细胞介素 2 (IL 2 )水平变化分析其可能的机理。方法 对 5 2例乙型肝炎表面抗原 (HBsAg)阳性孕妇分娩的新生儿行乙型肝炎免疫球蛋白和乙型肝炎疫苗 (HBVac)联合免疫接种 ,7个月时进行随访。用巢式聚合酶链反应 (nested PCR)技术检测新生儿血清和PBMC中HBVDNA ,固相放射免疫法检测血清乙型肝炎表面抗体 (HBsAb) ,采用体外细胞培养和双抗体夹心酶联免疫法检测PBMC在植物血凝素 (PHA)和HBsAg刺激下 ,培养上清液中IL 2的含量。结果 HBV侵犯PBMC后 ,新生儿免疫接种的失败率为 73 3% ,显著高于PBMC未受侵犯新生儿的 5 4 % ,差异有显著性 (P<0 0 5 ) ;免疫接种失败新生儿的PBMC培养上清液中 ,IL 2含量为 (85± 37)ng/L(PHA刺激 )、(5 1±18)ng/L(HBsAg刺激 ) ,明显低于免疫接种成功者和正常对照 ,差异均有显著性 (P值均 <0 0 5 )。结论 宫内感染HBV并侵犯PBMC ,是新生儿免疫接种失败的重要原因 ;HBV侵犯PBMC可使其IL 2分泌能力下降 。 | 孟金来 岳亚飞 张树林 | 2002 | 中华妇产科杂志2002，37，3： | 17 |
| 11 | 转化生长因子β1与乙型肝炎肝血管病变的关系显示文摘目的研究肝组织中转化生长因子β1(TGF-β1)的表达与慢性乙型肝炎(CHB)肝血管增生及肝血管纤维化的关系方法 CHB标本120例,CCl_4实验鼠肝标本50例进行TGF-β1免疫组织化学(免疫组化)染色及TGF-β1 mRNA原位杂交,并检测了CHB肝组织中α-SMA,FN,LN,Co-Ⅳ表达与TGF-β1的关系结果在CHB Ⅰ组TGF-β1阳性表达占93%,强阳性表达为70%;在CHB Ⅱ组其阳性表达占43%,强阳性表达为57%;在CHB Ⅲ组其强阳性表达占77%,阳性表达为23%;而在肝硬变(LC)组TGF-β1则皆示强阳性表达(100%),其间有极显著性差异(P<0.01)原位杂交显示,TGF-β1mRNA主要分布于血管纤维化区域、肝窦壁及部分肝细胞,同时TGF-β1在肝组织中的表达与α-SMA,FN,LN及Co-Ⅳ呈同步关系结论TGF-β1通过激活血管及肝窦内皮细胞,引发肝血管增生及内皮细胞凋亡,在细胞外基质等参与下,最终导致肝血管纤维化、肝窦毛细血管化及假小叶纤维间隔形成. | 严家春 陈文笔 马勇 田瑞霞 丁体龙 徐长江 | 2001 | 世界华人消化杂志2001，9，7： | 14 |
| 12 | 乙肝病毒母婴垂直传播阻断的研究显示文摘目的:研究乙型肝炎表面抗原(HBsAg)携带者孕妇及其新生儿应用乙肝免疫球蛋白(HBIG)对阻断乙肝母婴传播的效果。方法:A组66例,于孕28、32、36周分别注射HBIG200U,B组68例仅常规产前检查及监护。新生儿分为Ⅰ、Ⅱ、Ⅲ组,Ⅰ、Ⅱ组新生儿注射乙肝疫苗(HBVac)10μg和HBIG100U,Ⅲ组新生儿只注射HBVac10μg。结果:A组较B组新生儿出生时外周血HBsAg阳性率显著降低,P<0.05。Ⅰ、Ⅲ组婴儿6月龄HBsAb阳性率差异有显著性,P<0.05。结论:对HBsAg携带者孕晚期应用HBIG可以显著降低新生儿外周血HBsAg阳性率;对HBsAg携带者孕晚期应用HBIG,新生儿出生时应用HBIG和HBVac联合免疫,可以显著提高婴儿6月龄HBsAb的阳性率。 | 孟钊 肖小敏 何明娇 徐玉苑 李耘 | 2005 | 实用妇产科杂志2005，21，6： | 13 |
| 13 | 乙型肝炎表面抗原与乙型肝炎e抗原阴性孕妇乙型肝炎病毒宫内感染的研究显示文摘目的探讨应用套式PCR方法检测乙型肝炎表面抗原(HBsAg)及乙型肝炎e抗原(HBeAg)阴性孕妇乙型肝炎病毒(HBV)宫内感染的状况。方法选择HBsAg与HBeAg阴性,其他HBV血清标志物阳性孕妇及其新生儿24例作为病例组,同期HBV血清标志物全部阴性孕妇及其新生儿16例作为对照组。采用套式PCR方法检测两组孕妇及其新生儿的血清及外周血单个核细胞(PBMC)中HBVDNA。结果(1)病例组24例孕妇中,血清HBVDNA阳性8例,阳性率为33%;PBMC中HBVDNA阳性10例,阳性率为42%。其中血清与PBMC均阳性3例,总阳性率为63%(15/24)。(2)病例组24个新生儿中,血清HBVDNA阳性3例,阳性率为13%,PBMC中HBVDNA阳性6例,阳性率为25%。其中血清与PBMC均阳性1例,宫内感染率为33%(8/24)。(3)病例组24例孕妇中,血清阴性而PBMC阳性共7例,其新生儿4例发生宫内感染,感染率为4/7。(4)对照组16例孕妇及其新生儿血清及PBMC中HBVDNA全部阴性。结论HBsAg及HBeAg阴性孕妇也可发生HBV宫内感染,采用灵敏度高的套式PCR方法检测孕妇及其新生儿血清及PBMC中HBVDNA,对诊断HBV宫内感染具有重要临床意义。 | 归巧娣 岳亚飞 李淑红 张芬 | 2005 | 中华妇产科杂志2005，40，2： | 13 |
| 14 | HBIG联合乙肝疫苗阻断乙肝病毒母婴垂直传播的研究显示文摘探讨阻断乙肝病毒母婴垂直传播的方法。将166例HBsAg(+)孕妇分成三组,第一组婴儿注射乙肝疫苗(HBVac);第二组婴儿肌注乙肝免疫球蛋白(HBIG)加HBVac;第三组母亲于妊娠28、32、36周各肌注HBIG,婴儿用HBIG和HBVac(同第二组),血清检测HBVM采用ELISA法。21个月龄儿HBeAg阳性率分别为29.1%、20%、5.36%。孕晚期给予HBIG和婴儿给予。HBIG和HBVac联合治疗可有效阻断母婴垂直传播。 | 郭艳巍 刘新伟 | 2004 | 临床肝胆病杂志2004，20，4： | 12 |
| 15 | 孕妇及其新生儿乙肝病毒标志物与胎儿宫内感染的关系显示文摘目的探讨乙型肝炎表面抗原(HBsAg)阳性孕妇及其新生儿乙肝标志物与胎儿宫内感染的关系,以对高危人群采取适当的预防措施,降低宫内感染的发生率。方法对437例HBsAg阳性孕妇及其新生儿进行乙型肝炎病毒(HBV)DNA含量和HBV标志物的定量检测。结果孕妇与其分娩新生儿HBV DNA含量比较差异有显著统计学意义(P<0.001);孕妇HBeAg滴度与其新生儿HBeAg滴度有一定的伴随关系(P<0.01)。结论对HBsAg及HBV DNA阳性的孕妇产前给予多次注射乙肝高效价免疫球蛋白,可以有效降低胎儿宫内HBV感染的发生率。 | 王建芳 唐讯 王建玲 | 2007 | 现代医学2007，35，4： | 11 |
| 16 | Distribution of nitric oxide synthase in stomach myenteric plexus of rats显示文摘AIM: To study the distribution of nitric oxide synthase (NOS) in rat stomach myenteric plexus.METHODS: The distribution of NOS in gastric wall was studied in quantity and location by the NADPH-diaphorase (NDP) histochemical staining method and whole mount preparation technique.RESULTS: NOS was distributed in whole stomach wall, most of them were located in myenteric plexus, and distributed in submucosal plexus. The shape of NOS positive neurons was basically similar, most of them being round and oval in shape. But their density, size and staining intensity varied greatly in the different parts of stomach. The density was 62 -± 38 cells/mm2(antrum), 43 ± 32 cells/mm2(body), and 32 ± 28 cells/mm2 (fundus), respectively. The size and staining intensity of NOS positive neurons in the fundus were basically the same, the neurons being large and dark stained, while they were obviously different in antrum. In the body of the stomach, the NOS positive neurons were in an intermediate state from fundus to antrum. There were some beadlike structures which were strung together by NOS positive varicosities in nerve fibers, some were closely adherent to the outer walls of blood vessels.CONCLUSION: Nitric oxide might he involved in the modulation of motility, secretion and blood ciroulation of the stomach, and the significant difference of NOS positive neurons in different parts of stomach myenteric plexus may be related to the physiologic function of stomach. | Xi Peng Jin-Bin Feng Hong Yan Yun Zhao Shi-Liang Wang Institute of Burn Research,Southwest Hospital,Third Military Medical University,Chongqing 400038,China | 2001 | World Journal of Gastroenterology2001，7，6： | 11 |
| 17 | HBV母婴传播致新生儿免疫接种失败的原因显示文摘目前在 HBV母婴传播的各种阻断措施中 ,用 HB疫苗或联合免疫球蛋白 ( HBIG)阻断 HBV母婴传播的效果 ,已十分肯定 ,但仍有 10 % - 2 0 %高危产儿 (其母亲为 HBs Ag和 /或 HBe Ag阳性 )不能得到疫苗的保护 ,即免疫失败。造成免疫接种失败的原因很多 ,本文重点从宫内感染。 | 孟金来 岳亚飞 | 2001 | 国外医学(妇幼保健分册)2001，12，2： | 10 |
| 18 | 乙肝免疫球蛋白和乙肝疫苗联合阻断宫内感染的疗效观察显示文摘目的:探讨不同方法阻断母婴垂直传播的效果. 方法:将120例HBsAg和(或)HBeAg阳性的孕妇分成3组, A组42例给予乙肝免疫球蛋白和乙肝疫苗治疗,B组40例给 予乙肝疫苗治疗,C组38例,未给任何治疗.A组和B组均在 孕20wk时开始注射,用ELISA检测孕妇HBV血清标志物和 新生儿的血清HBsAg.结果:新生儿A组感染率为7% (3/42).B组感染率为30%(12/40).C组感染率为37% (14/38).A组HBV感染率明显低于B组与C组(P< 0.01).结论:携带乙肝病毒孕妇于孕晚期给乙肝免疫球蛋白 和乙肝疫苗联合治疗可有效地降低婴儿HBV感染率,表明干 预性治疗可有效阻断HBV宫内传播. | 段文斌 王伯良 周小平 仲月霞 | 2005 | 第四军医大学学报2005，26，2： | 10 |
| 19 | HBsAg阳性孕妇血清HBV-DNA含量与胎儿宫内感染显示文摘目的:通过对血液HBsAg阳性孕妇及其所生婴儿进行荧光定量PCR方法检测HBV-DNA含量,探讨母体血中HBV-DNA含量与胎儿宫内感染HBV的关系。方法:选择住院分娩的HBsAg阳性孕妇,使用荧光定量PCR方法检测孕妇及其新生儿脐血血清中HBV-DNA含量。结果:128例HBsAg阳性孕妇分娩的婴儿中有27例脐带血HBV-DNA阳性,即宫内感染率为21.09%(27/128)。HBsAg阳性孕妇中PCR检测HBV-DNA阳性的孕妇宫内感染率为28.13%(27/96)。孕妇血清HBV-DNA含量<103copy/ml无一例婴儿发生宫内感染;宫内感染主要发生在血清HBV-DNA含量≥105copy/ml的孕妇,发生率为50%(26/52);HBV-DNA含量≥108copy/ml的孕妇其新生儿感染乙肝的几率显著增高(84.62%)。结论:HBsAg阳性孕妇可发生HBV宫内感染,随着孕妇血清HBV-DNA含量的升高宫内感染率逐渐增高,阻断HBV的宫内感染,必须有效降低孕妇血中的HBV-DNA含量水平。 | 陈秀华 | 2010 | 吉林医学2010，31，17： | 10 |
| 20 | 联合免疫阻断HBV宫内传播的临床效果评价显示文摘目的 探讨母婴联合免疫阻断乙型肝炎 (乙肝 )病毒宫内传播的效果。方法 将 2 16例乙肝表面抗原阳性孕妇随机分组 ,母婴联合组 12 6例 ,自孕 2 8周起注射乙肝免疫球蛋白 (HBIG)2 0 0U ,新生儿 0、15天各注射HBIG 2 0 0U ,然后于 1、2、7个月龄各接种乙肝疫苗 (HBVac) 2 0 μg。对照组 90例 ,只对新生儿进行免疫。母儿血清检测采用美国Abbott酶联免疫试剂测定 ,随访 1年。结果 联合免疫组婴儿宫内感染率低于对照 (19 5 1%与 35 5 6 %) , 慢性HBV感染率由 13 33%降为 3 97%,P均 <0 0 5 ;联合免疫组及对照组新生儿出生时抗HBs检出率 (80 95 %与 0 )及 1岁时保护性抗体产生率 (96 0 3%与 86 6 7%)均明显高于对照组 ,P均 <0 0 5。结论 孕妇及婴儿联合免疫可有效预防宫内感染且明显提高宫内感染阻断效果 ,减少慢性HBV感染率。 | 韩国荣 余敏敏 沈玲 唐讯 吴垊垊 张小燕 岳欣 | 2003 | 江苏医药2003，29，11： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员